Adalimumab vs. Conventional Immunosuppression for Uveitis

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Adalimumab vs. Conventional Immunosuppression for Uveitis

Listen for free

View show details

About this listen

Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial."

Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press.

Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

No reviews yet